I have invested in dividends for 11 years — These income machines pay me every quarter like clockwork

Dividend investing stands out as a reliable path to building wealth because it turns company profits into a steady cash stream for shareholders. Chasing high-growth stocks can mean absorbing wild swings with every shift in market sentiment. Dividends, by contrast, provide predictable income that compounds over time through reinvestment.

This strategy suits long-term investors by reducing volatility. Regular payouts act as a buffer during downturns, letting you accumulate more shares at lower prices. For retirees or those pursuing financial independence, dividends offer a hands-off way to generate passive income without liquidating assets.

Historically, dividend payers have outperformed non-payers, delivering both capital appreciation and yields that beat inflation. The three dividend stocks below are the workhorses of my portfolio, paying me dividends every quarter like clockwork.

Cardinal Health (CAH)

Cardinal Health (NYSE:CAH | CAH Price Prediction) ranks as a dividend star because of its essential role in the U.S. healthcare supply chain, distributing pharmaceuticals and medical products to hospitals and pharmacies nationwide. That positioning generates consistent revenue even in economic slowdowns, since demand for drugs and medical supplies remains largely inelastic.

The company currently pays a quarterly dividend of $0.5158 per share, yielding roughly 1% annually. Its payout ratio sits around 28%, which means dividends consume only a modest slice of earnings, leaving substantial cash for reinvestment in operations and growth.

What makes CAH stand out is its nearly four decades of consecutive dividend increases, qualifying it as a Dividend Aristocrat and reflecting disciplined financial stewardship across market cycles. Over that span, the payout has grown steadily, supported by operational efficiencies and market share gains in the pharmaceutical distribution industry. Future prospects look solid as aging populations continue to drive healthcare spending higher.

Cardinal’s focus on high-margin segments like specialty drugs and home health positions it to grow earnings steadily over time. Analysts expect modest stock appreciation alongside further dividend hikes, making it a low-risk anchor for income-focused investors. In my holdings, CAH’s clockwork-like payments have quietly compounded, proving its value across any market environment.

Altria (MO)

Altria (NYSE:MO) earns its status as a dividend dynamo through sky-high yields and a fortress-like business model built on iconic brands like Marlboro. As the leading U.S. cigarette maker, it commands pricing power in a declining but profitable market, where loyal adult smokers provide remarkably recession-resistant cash flows.

The quarterly dividend stands at $1.11 per share after a 4.7% increase announced in August 2026, delivering a yield of roughly 6.4% annually. That figure dwarfs the broader S&P 500 average by a wide margin. A payout ratio near 80% reflects Altria’s deep commitment to shareholders, backed by strong annual free cash flow.

This reliability stems from 57 years of consecutive dividend hikes, even as smoking rates have fallen. The August 2026 increase was Altria’s 61st dividend raise in that span. Altria has pivoted smartly into smokeless products, including oral nicotine pouches, where its on! brand grew shipment volumes by approximately 11% in 2025. That diversification cushions against regulatory headwinds, while ongoing product innovation expands reach in the fast-growing nicotine pouch category.

Looking ahead, with U.S. tobacco volumes stabilizing and non-combustible segments accelerating, the company targets mid-single-digit dividend per share growth annually through 2028. The stock’s defensive character has historically limited drawdowns during broader market sell-offs, producing total returns that blend a generous yield with modest price appreciation. For me, MO’s payments have been a portfolio staple, turning a mature industry into evergreen income.

Johnson & Johnson (JNJ)

Johnson & Johnson (NYSE:JNJ) rounds out the trio with a blend of innovation and stability across pharmaceuticals and medical devices. Its diversified portfolio of blockbuster drugs like Stelara and a broad line of orthopedic and surgical devices shields the company against single-product risks, producing reliable earnings from global demand.

In April 2026, Johnson & Johnson raised its quarterly dividend to $1.34 per share, a 3.1% increase that lifted the annualized payout to $5.36. At recent prices, the stock yields close to 2%, supported by a manageable payout ratio that allows for continued heavy R&D investment without strain.

JNJ’s allure lies in 64 straight years of dividend growth, the longest active streak of any major healthcare company and a hallmark of its Dividend King status. This track record reflects prudent capital allocation, with free cash flow projected at roughly $21 billion for 2026. The 2023 spin-off of consumer health into Kenvue (NYSE:KVUE) sharpened the company’s focus on high-growth pharma and medtech, where the pipeline targets oncology and immunology.

With patents protecting key revenue streams and an aging global population boosting demand for procedures and therapies, analysts forecast steady earnings growth into the late 2020s. JNJ offers defensive upside, remaining stable during volatility, with total returns that have historically been competitive over long horizons. In my portfolio, it is the blue-chip engine driving quarterly reliability.

Editor’s note: This update corrects Cardinal Health’s dividend streak to nearly four decades of consecutive annual raises and updates its quarterly dividend to $0.5158 per share; raises Altria’s quarterly dividend to $1.11 (reflecting the August 2026 increase, its 61st raise in 57 years) and replaces the unverified 40% on! volume claim with the SEC-filed 2025 figure of approximately 11% shipment growth; and updates Johnson & Johnson’s quarterly dividend to $1.34 per share and its consecutive-increase streak to 64 years.

Contact [email protected] for any questions or corrections.